England’s National Health Service announced that it will fund treatments with Roche’s Hemlibra (emicizumab) for 2,000 Hemophilia A patients.

The injected antibody is designed to prevent uncontrolled bleeding by mimicking the action of the blood protein factor VIII, replacing multiple infusions every week to one injection per week.

The funding decision was part of the NHS long term plan to expand access to advanced medical interventions.